US EditionAstria Therapeutics Licenses Navenibart to Kaken Pharmaceutical for Hereditary Angioedema Treatment in Japan
Summary by GeneOnline News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Astria Therapeutics Licenses Navenibart to Kaken Pharmaceutical for Hereditary Angioedema Treatment in Japan
Astria Therapeutics has entered into an exclusive licen […] The post Astria Therapeutics Licenses Navenibart to Kaken Pharmaceutical for Hereditary Angioedema Treatment in Japan first appeared on GeneOnline News. The post Astria Therapeutics Licenses Navenibart to Kaken Pharmaceutical for Hereditary Angioedema Treatment in Japan appeared first on GeneOnline News.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
